Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Taurursodiol

FDA-approved product (for suspension, oral).

Registered studies
43
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Taurursodiol
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Taurursodiol. Its therapeutic class is shown instead.

WHO therapeutic group
Bile acids and derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA79.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli17.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis46.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

43registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Taurursodiol in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Taurursodiol with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Integrative Liver-Targeted Therapy for Diabetic Macular Edema: Using "Tauroursodeoxycholate" or Traditional Chinese Medicine.

    NCT07457632 · start 2026-10-01

    Registered record
    Registry ID
    NCT07457632
    Conditions
    Diabetic Macular Edema (DME)
    Interventions
    Tauroursodeoxycholate (TUDCA); Traditional Chinese Medicine (mQJDHW); placebo capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10-01
    Completion
    2028-12-31
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Macular Edema (DME)
    InterventionTauroursodeoxycholate (TUDCA); Traditional Chinese Medicine (mQJDHW); placebo capsule
    PhasePhase 2
    Registry statusNot yet recruiting

  • METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)

    NCT07699380 · start 2026-09

    Registered record
    Registry ID
    NCT07699380
    Conditions
    Type 1 Diabetes (T1D); Metabolic Diseases; Glucose Metabolism Disorders; Endocrine System Diseases; Autoimmune Diseases; Immune System Diseases; Diabetes Melletus, Type 1; Nutritional and Metabolic Diseases; Combination Therapy
    Interventions
    AMX0035; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-09
    Completion
    2029-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 1 Diabetes (T1D); Metabolic Diseases; Glucose Metabolism Disorders; Endocrine System Diseases +5 more
    InterventionAMX0035; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • TUDCA in High-Risk Lactating Mothers Identified by Early Postpartum Milk Hydrophobicity Index

    NCT07517276 · start 2026-04-02

    Registered record
    Registry ID
    NCT07517276
    Conditions
    Metabolic Dysfunction-Associated Steatotic Liver Disease Infant Development
    Interventions
    tauroursodeoxycholic acid (TUDCA); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-04-02
    Completion
    2026-07-30
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetabolic Dysfunction-Associated Steatotic Liver Disease Infant Development
    Interventiontauroursodeoxycholic acid (TUDCA); Placebo
    PhasePhase 2
    Registry statusNot yet recruiting

  • Effect of Oral Supplement on Influenza Vaccine Long-term Response

    NCT07357467 · start 2026-03

    Registered record
    Registry ID
    NCT07357467
    Conditions
    Influenza; Immunosenescence
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-03
    Completion
    2026-07
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfluenza; Immunosenescence
    InterventionNot recorded
    PhaseNot recorded
    Registry statusNot yet recruiting

  • A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma

    NCT07328009 · start 2026-01-19

    Registered record
    Registry ID
    NCT07328009
    Conditions
    Hepato Cellular Carcinoma (HCC)
    Interventions
    Lenvatinib; Regorafenib (BAY 73-4506); Tislelizumab+TKI; HAIC+TKI; HAIC + Tislelizumab+TKI; QL1706+TKI; HAIC + QL1706+TKI; TUDCA + Camrelizumab+TKI; XELOX + QL1706+TKI; XELOX + Tislelizumab+TKI
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-01-19
    Completion
    2029-01-15
    Enrolment
    350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepato Cellular Carcinoma (HCC)
    InterventionLenvatinib; Regorafenib (BAY 73-4506); Tislelizumab+TKI; HAIC+TKI +6 more
    PhasePhase 2
    Registry statusRecruiting

  • Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab

    NCT07100392 · start 2025-08-14

    Registered record
    Registry ID
    NCT07100392
    Conditions
    Hepatocellular Carcinoma (HCC)
    Interventions
    tauroursodeoxycholic acid (TUDCA); Camrelizumab; Regorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-08-14
    Completion
    2028-08-01
    Enrolment
    141

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatocellular Carcinoma (HCC)
    Interventiontauroursodeoxycholic acid (TUDCA); Camrelizumab; Regorafenib
    PhasePhase 2
    Registry statusRecruiting

  • Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study

    NCT07064668 · start 2025-07-30

    Registered record
    Registry ID
    NCT07064668
    Conditions
    Hepatocellular Carcinoma
    Interventions
    TUDCA (Tauroursodeoxycholic Acid) Supplementation; Immune checkpoint inhibitor (ICI)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-07-30
    Completion
    2027-12-30
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatocellular Carcinoma
    InterventionTUDCA (Tauroursodeoxycholic Acid) Supplementation; Immune checkpoint inhibitor (ICI)
    PhasePhase 2
    Registry statusNot yet recruiting

  • Effect of Oral Supplements for Influenza Vaccine Response

    NCT06827873 · start 2025-02

    Registered record
    Registry ID
    NCT06827873
    Conditions
    Influenza Vaccine Response
    Interventions
    ARA (Arachidonic Acid) Supplementation; TUDCA (Tauroursodeoxycholic Acid) Supplementation; Placebo Supplementation; Shanghai Biological Quadrivalent Influenza Virus Inactivated Vaccine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2025-02
    Completion
    2025-10
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfluenza Vaccine Response
    InterventionARA (Arachidonic Acid) Supplementation; TUDCA (Tauroursodeoxycholic Acid) Supplementation; Placebo Supplementation; Shanghai Biological Quadrivalent Influenza Virus Inactivated Vaccine
    PhaseNot applicable
    Registry statusNot yet recruiting

  • AMX0035 and Progressive Supranuclear Palsy

    NCT06122662 · start 2023-12-21

    Registered record
    Registry ID
    NCT06122662
    Conditions
    Progressive Supranuclear Palsy; PSP; Neurodegenerative Diseases; Atypical Parkinsonism
    Interventions
    AMX0035; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2023-12-21
    Completion
    2025-10-21
    Enrolment
    139

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProgressive Supranuclear Palsy; PSP; Neurodegenerative Diseases; Atypical Parkinsonism
    InterventionAMX0035; Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial

    NCT04244630 · start 2023-11-02

    Registered record
    Registry ID
    NCT04244630
    Conditions
    Amyotrophic Lateral Sclerosis (ALS)
    Interventions
    Antioxidants
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2023-11-02
    Completion
    2026-12
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmyotrophic Lateral Sclerosis (ALS)
    InterventionAntioxidants
    PhasePhase 2
    Registry statusActive not recruiting

  • Targeting Endoplasmic Reticulum Stress in Human Hypertension

    NCT06025630 · start 2023-08-15

    Registered record
    Registry ID
    NCT06025630
    Conditions
    Hypertension
    Interventions
    TUDCA; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2023-08-15
    Completion
    2028-12-31
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionTUDCA; Placebo
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • AMX0035 in Adult Patients With Wolfram Syndrome

    NCT05676034 · start 2023-03-03

    Registered record
    Registry ID
    NCT05676034
    Conditions
    Wolfram Syndrome
    Interventions
    AMX0035
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2023-03-03
    Completion
    2028-05-31
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionWolfram Syndrome
    InterventionAMX0035
    PhasePhase 2
    Registry statusActive not recruiting

  • Extension Study Evaluating The Safety And Tolerability of AMX0035

    NCT05619783 · start 2022-12-29

    Registered record
    Registry ID
    NCT05619783
    Conditions
    Amyotrophic Lateral Sclerosis
    Interventions
    AMX0035
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-12-29
    Completion
    2024-10-30
    Enrolment
    352

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmyotrophic Lateral Sclerosis
    InterventionAMX0035
    PhasePhase 3
    Registry statusCompleted

  • Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment

    NCT05021536 · start 2021-10-28

    Registered record
    Registry ID
    NCT05021536
    Conditions
    Amyotrophic Lateral Sclerosis
    Interventions
    Placebo; AMX0035
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2021-10-28
    Completion
    2026-01-01
    Enrolment
    664

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmyotrophic Lateral Sclerosis
    InterventionPlacebo; AMX0035
    PhasePhase 3
    Registry statusUnknown

  • Open Label Extension of TUDCA-ALS Study

    NCT05753852 · start 2021-10-25

    Registered record
    Registry ID
    NCT05753852
    Conditions
    Amyotrophic Lateral Sclerosis
    Interventions
    Tauroursodeoxycholic Acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2021-10-25
    Completion
    2025-03-31
    Enrolment
    184

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmyotrophic Lateral Sclerosis
    InterventionTauroursodeoxycholic Acid
    PhasePhase 3
    Registry statusUnknown